La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Edesa Biotech Croissance future

Future contrôle des critères 0/6

Les bénéfices de Edesa Biotech devraient diminuer de 32.7% par an. Le BPA devrait augmenter de 16.6% par an.

Informations clés

-32.7%

Taux de croissance des bénéfices

16.6%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.2%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	20 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:EDSA - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2026	N/A	-14	N/A	N/A	1
9/30/2025	N/A	-11	N/A	N/A	2
9/30/2024	N/A	-8	N/A	N/A	2
6/30/2024	N/A	-7	-5	-5	N/A
3/31/2024	N/A	-7	-6	-6	N/A
12/31/2023	N/A	-8	-6	-6	N/A
9/30/2023	N/A	-8	-7	-7	N/A
6/30/2023	N/A	-9	-11	-11	N/A
3/31/2023	N/A	-13	-12	-12	N/A
12/31/2022	N/A	-16	-11	-11	N/A
9/30/2022	N/A	-18	-12	-12	N/A
6/30/2022	N/A	-18	-7	-7	N/A
3/31/2022	N/A	-17	-7	-7	N/A
12/31/2021	N/A	-15	-14	-14	N/A
9/30/2021	N/A	-13	-14	-14	N/A
6/30/2021	0	-12	-15	-15	N/A
3/31/2021	0	-9	-13	-13	N/A
12/31/2020	0	-8	-7	-7	N/A
9/30/2020	0	-6	-5	-5	N/A
6/30/2020	1	-5	-5	-5	N/A
3/31/2020	1	-5	-6	-6	N/A
12/31/2019	1	-4	-6	-6	N/A
9/30/2019	0	-3	-5	-5	N/A
6/30/2019	0	-3	-4	-4	N/A
3/31/2019	N/A	-2	-1	-1	N/A
12/31/2018	N/A	-2	-1	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: EDSA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: EDSA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: EDSA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de EDSA devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: EDSA ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de EDSA devrait être élevé dans 3 ans

Edesa Biotech Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 35% to US$24.00

Price target decreased by 10% to US$52.33

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to US$16.33

No longer forecast to breakeven

Recent updates

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech, Inc., Annual General Meeting, May 30, 2024

Price target decreased by 35% to US$24.00

Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech’S ARDS Drug

Price target decreased by 10% to US$52.33

Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government

New major risk - Market cap size

New minor risk - Share price stability

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023

Edesa Biotech Receives Non-Compliance Notice From Nasdaq

Less than half of directors are independent

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech, Inc. Reports Topline Phase 2B Results for Dermatology Drug

Fda Grants Fast Track to Edesa Biotech's Ards Drug Candidate

No longer forecast to breakeven

Insufficient new directors

Edesa Biotech, Inc. announced that it has received CAD 3.027754 million in funding

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech, Inc. Reports Phase 2b Study Reaches Full Enrollment

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

No longer forecast to breakeven

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Edesa Biotech, Inc. Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

Price target decreased to US$16.33

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

High number of new and inexperienced directors

No longer forecast to breakeven

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa Biotech, Inc., Annual General Meeting, May 18, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to Its Board of Directors

Edesa Biotech, Inc. Announces Peter Van Der Velden Resign from Board and Its Committees

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Edesa Biotech, Inc. Announces Positive Phase 2 Data of Monoclonal Antibody in Hospitalized Covid-19 Patients

Edesa Biotech, Inc. Provides Update on Phase 2/3 Clinical Study Evaluating its Monoclonal Antibody Candidate as Single-Dose Therapy for Hospitalized COVID-19 Patients

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech, Inc. Extends Dermatitis Study to Canada

Edesa Biotech, Inc. Completes Independent Data and Safety Monitoring Board Interim Review of COVID-19 Drug Candidate

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Edesa Biotech, Inc. Completes Enrollment of More Than 50% of the Patients Planned for the Phase 2 Portion of Its Ongoing Phase 2/Phase 3 Clinical Study

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

Edesa Biotech, Inc., Annual General Meeting, Apr 22, 2021

Price target raised to US$17.00

Director recently sold US$58k worth of stock

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Earnings beat expectations, revenue disappoints

Edesa Biotech receives C$14M for COVID-19 study

New 90-day high: US$7.48

New 90-day low: US$4.25

New 90-day low: US$4.63

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Full year 2020 earnings released: US$0.74 loss per share

Revenue and earnings beat expectations

Edesa Biotech EPS misses by $0.04, beats on revenue

New 90-day low: US$5.40

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

New 90-day high - US$9.45

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action